Hidrocortisona

Hydrocortisona, containing the active ingredient hydrocortisone sodium succinate, is a prescription‑only corticosteroid administered by intramuscular or intravenous injection. It belongs to the glucocorticoid therapeutic class and is marketed in the European Union. The formulation is designed for rapid systemic delivery, allowing clinicians to address acute endocrine or inflammatory emergencies. Hydrocortisona is not available over the counter and requires medical supervision and careful dosing considerations by qualified providers.

Hydrocortisona is indicated for several acute and chronic conditions that require rapid glucocorticoid replacement or anti‑inflammatory action.

- Treatment of adrenal insufficiency, including Addison’s disease and acute adrenal crisis. - Management of severe shock where cortisol deficiency contributes to hemodynamic instability. - Rapid control of life‑threatening allergic or inflammatory reactions, such as anaphylaxis or severe asthma exacerbations. - Adjunct therapy in postoperative or trauma patients to reduce systemic inflammation. - Supportive care in patients with congenital adrenal hyperplasia during stress periods.

Like all systemic glucocorticoids, hydrocortisone sodium succinate may cause a range of adverse reactions, varying from mild and transient to potentially serious.

Common: - Transient hyperglycemia or elevated blood glucose levels. - Mild electrolyte disturbances such as sodium retention or potassium loss. - Local injection site pain, erythema, or swelling. - Gastrointestinal discomfort, including nausea or dyspepsia. - Mood changes such as irritability or insomnia.

Serious: - Severe hyperglycemia leading to diabetic ketoacidosis. - Significant hypertension or fluid overload. - Acute adrenal suppression after abrupt discontinuation. - Infections that become more severe due to immunosuppression. - Allergic reactions ranging from urticaria to anaphylaxis.

Clinicians should evaluate patient history and clinical status before initiating hydrocortisone sodium succinate to minimize risks.

- Assess for uncontrolled diabetes, hypertension, or existing electrolyte imbalances. - Use the lowest effective dose for the shortest duration necessary. - Monitor blood glucose and blood pressure regularly during therapy. - Avoid abrupt cessation; taper the dose when long‑term treatment is required. - Consider alternative therapy in patients with active systemic infections. - Evaluate pregnancy and lactation status, as safety data are limited. - Review renal or hepatic impairment, which may affect drug clearance.

Hydrocortisone sodium succinate can interact with several medications, altering its efficacy or increasing adverse effects.

Avoid: - Concurrent use of potent CYP3A4 inducers (e.g., rifampin, phenytoin) that may reduce glucocorticoid levels. - High‑dose non‑steroidal anti‑inflammatory drugs (NSAIDs) that increase the risk of gastrointestinal bleeding. - Live vaccines, as immunosuppression may diminish vaccine effectiveness.

Use with caution: - Anticoagulants (e.g., warfarin) because glucocorticoids may enhance anticoagulant effects. - Diuretics, particularly thiazides, which can exacerbate electrolyte disturbances. - Antidiabetic agents, as glucocorticoids may raise blood glucose and require dose adjustments.